Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation

Table 6 Important studies on antiviral therapy in hepatitis-B-related acute on chronic liver failure

Ref.	Country	Study design	Drugs/dose	No of patients treated	End events	Follow up	Remarks
Yang et al[79]	China	RCT	Entecavir (0.5 mg)	55	Liver function, HBV DNA	1 mo	Useful
Sun et al[50]	China	Retrospective cohort	LAM (100 mg)	130	Mortality, DNA, YMDD mutation	3 mo	Not useful
Qiu et al[80]	China	RCT	Telbivudine (600 mg)	30	Liver function, HBV DNA	1 mo	Useful
Cui et al[58]	China	Retrospective cohort	LAM (100 mg) or EVT (0.5 mg)	67 (LAM) vs EVT (37)	Mortality, MELD, HBV DNA, recurrence	12 mo	Similar
Zhang et al[72]	China	Observational study	LAM (100 mg) plus Dexamethasone (10 mg/d, 5 d)	56	Liver function, MELD, Survival	1 mo	Useful
Garg et al[62]	India	RCT	Tenofovir (300 mg) vs placebo	14 vs 27	Mortality, MELD, HBV DNA	3 mo	Useful
Chen et al[60]	China	Retrospective cohort	LAM (100 mg) or EVT (0.5 mg)	72 (LAM) vs 34 (EVT)	Mortality, recurrence, HBV DNA, YMDD mutation	7 mo	Similar
Chen et al[47]	China	RCT	LAM (100 mg) or EVT (0.5 mg)	42(EVT) vs 30(LAM)	HBV DNA, YMDD mutation, MELD Na	7 mo	Evt more useful
Qin et al[81]	China	RCT	Telbivudine (600 mg)	12	Mortality, liver function, HBV DNA	3 mo	Useful in renal dysfunction
Lai et al[54]	China	RCT	LAM (100 mg) or EVT (0.5 mg)	93(EVT) vs 89(LAM)	HBV DNA, MELD, HBeAg -ve	3 mo	Evt useful
Chen et al[82]	China	RCT	Entecavir (0.5 mg) plus Dexamethasone (10 mg/d, 3 d)	31	Liver function, MELD, Mortality	3 mo	Useful

HBV: Hepatitis B virus.